Viemed pairs industry-leading 28% revenue growth and strong cash conversion with a stock trading near its highs where the engine's asymmetry gate has failed - leverage risk, overbought momentum, and modest insider selling temper an otherwise fundamentally sound growth story.
Thesis pillars
- Industry Leading Revenue Growth→Stable
- Asymmetry Gate Signals Limited Upside→Stable
- Strong Cash Conversion And Piotroski Score→Stable
- +2 more pillars — see the Why tab for full reasoning
Viemed Healthcare, Inc. (VMD) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $12.14, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (2.2% away).
Viemed Healthcare provides home medical equipment and post-acute healthcare services in the United States, focused on respiratory, chronic-care, and women's health products across all 50 states. Revenue comes primarily from Medicare, Medicaid, and private-insurer reimbursement... Read more
Hold if already holding. Not a fresh buy at $12.14, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (2.2% away). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.6/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 29d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerMedicare program10-K Item 1A: 'We earn revenues by seeking reimbursement for our products and services from governmental healthcare programs and private health insurance companies, primarily from the federal Medicare program.'
- MEDIUMSuppliera few equipment manufacturers10-K Item 1A: 'Dependence on only a few manufacturers presents risks that suppliers may not be able to provide or adequately provide sufficient equipment to satisfy demand.'
Material Events(8-K, last 90d)
- 2026-06-04Item 5.02LOWAt its June 4, 2026 Annual Meeting, shareholders approved a second amendment to the 2024 Long Term Incentive Plan, raising shares reserved for issuance to 7,696,717. Routine equity-plan amendment, not an officer departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $12.14, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (2.2% away). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $12.16 (+0.2%), stop $11.32 (−7.2%), A.R:R -1.5:1. Score 5.6/10, moderate confidence.
Take-profit target: $12.16 (+0.2% upside). Target $12.16 (+0.2%), stop $11.32 (−7.2%), A.R:R -1.5:1. Stop-loss: $11.32.
Analyst target reached - limited upside remaining; Near 52-week high (2.2% away); Overbought (RSI 86).
Viemed Healthcare, Inc. trades at a P/E of 32.8 (forward 30.3). TrendMatrix value score: 4.8/10. Verdict: Hold.
6 analysts cover VMD with a consensus score of 4.0/5. Average price target: $11.
What does Viemed Healthcare, Inc. do?Viemed Healthcare provides home medical equipment and post-acute healthcare services in the United States, focused on...
Viemed Healthcare provides home medical equipment and post-acute healthcare services in the United States, focused on respiratory, chronic-care, and women's health products across all 50 states. Revenue comes primarily from Medicare, Medicaid, and private-insurer reimbursement for equipment rentals and clinical services, plus healthcare staffing; the company employs 401 licensed respiratory therapists, about 29% of its workforce.